Overview

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
Phase:
Phase 3
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Diclofenac